{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:34:34Z","timestamp":1761561274681},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,8,28]],"date-time":"2008-08-28T00:00:00Z","timestamp":1219881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Archives of Drug Info"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:bold>Background and Aims.\u2002<\/jats:bold> Tegaserod is a selective serotonin receptor (5\u2010HT<jats:sub>4<\/jats:sub>) agonist that relieves dysmotility symptoms associated with constipation. Here we explore its effects on functional dyspepsia symptoms and heartburn during continued proton pump inhibitor (PPI) treatment.<\/jats:p><jats:p><jats:bold>Methods.\u2002<\/jats:bold> In this multicenter pilot study, following a 2\u2010week screening\/baseline period, women with functional dyspepsia and persisting heartburn treated with PPIs received add\u2010on open\u2010label tegaserod 6\u2003mg twice daily (bid) for 4 weeks. Treatment responders were then randomized 1:1 to continue double\u2010blind tegaserod or placebo therapy for 6 weeks. Efficacy variables included the proportion of days with satisfactory relief of dyspepsia symptoms (early satiety, postprandial fullness and bloating) as well as the change in individual symptom severity scores for these three cardinal dyspepsia symptoms. Health\u2010related quality of life was evaluated using a validated questionnaire, the Nepean Dyspepsia Index. Adverse events (AEs) were monitored.<\/jats:p><jats:p><jats:bold>Results.\u2002<\/jats:bold> Of 101 women enrolled, 71 completed open\u2010label treatment, and 70 responders were randomized to double\u2010blind treatment. The proportion of days with satisfactory relief of dyspepsia symptoms (least squares mean, LSM) increased with tegaserod and placebo, to 0.69 and 0.62, respectively at study end (<jats:italic>P<\/jats:italic>\u2003=\u20030.366). Similarly, both groups showed improvements in the composite daily symptom severity score (overall LSM change from baseline of 1.55 and 1.57, <jats:italic>P<\/jats:italic>\u2003=\u20030.934), and the Nepean Dyspepsia Index (overall LSM change of \u221239.0 and \u221237.8, <jats:italic>P<\/jats:italic>\u2003=\u20030.537). Tegaserod was well tolerated. Diarrhea was the most common AE (8.1% tegaserod, 0% placebo). There were no serious AEs or deaths.<\/jats:p><jats:p><jats:bold>Conclusions.\u2002<\/jats:bold> A significant treatment effect was not demonstrated in this study using a treatment\u2010withdrawal methodology. In future studies of functional dyspepsia patients with heartburn, a more rigorous parallel\u2010group study design should be considered.<\/jats:p>","DOI":"10.1111\/j.1753-5174.2008.00012.x","type":"journal-article","created":{"date-parts":[[2008,8,28]],"date-time":"2008-08-28T13:38:38Z","timestamp":1219930718000},"page":"79-88","source":"Crossref","is-referenced-by-count":7,"title":["Exploratory Study of Tegaserod for Dyspepsia in Women Receiving PPIs for Heartburn"],"prefix":"10.1111","volume":"1","author":[{"given":"Nimish","family":"Vakil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farid","family":"Kianifard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Bottoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,12,15]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)70025-8"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.01897.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2006.03.008","volume-title":"Rome III. The functional gastrointestinal disorders","author":"Drossman DA","year":"2006"},{"key":"e_1_2_7_5_2","first-page":"A380","article-title":"Gastrointestinal symptom profile in patients with functional heartburn","volume":"126","author":"Rodriguez\u2010Stanley S","year":"2004","journal-title":"Gastroenterology"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.08.026"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.6.885"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00356-8"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40749.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01094.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01372.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.070789"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2005.00715.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)80265-2"},{"key":"e_1_2_7_15_2","first-page":"A94","article-title":"Effect of tegaserod, a 5\u2010HT4 receptor agonist, on sensory and motor function of the proximal stomach in functional dyspepsia","volume":"128","author":"Tack J","year":"2005","journal-title":"Gastoenterology"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03521.x"},{"key":"e_1_2_7_17_2","volume-title":"Rome II: The functional gastrointestinal disorders","author":"Drossman DA","year":"2000"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01363.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00900.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2004.04.004"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i17.2708"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02184.x"},{"key":"e_1_2_7_23_2","first-page":"31","article-title":"Functional dyspepsia and nonerosive reflux disease: Clinical interactions and their implications","volume":"9","author":"Keohane J","year":"2007","journal-title":"MedGenMed"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v11.i42.6577"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i17.2694"},{"key":"e_1_2_7_26_2","first-page":"A","article-title":"A phase II placebo controlled randomized trial with tegaserod (T) in functional dyspepsia (FD) with normal gastric emptying (NGE)","volume":"122","author":"Tack J","year":"2002","journal-title":"Gastroenterology"},{"key":"e_1_2_7_27_2","first-page":"A193","article-title":"Tegaserod, a partial 5\u2010HT4 agonist, in functional dyspepsia patients with normal gastric emptying: A randomized, double\u2010blind, placebo\u2010controlled trial","volume":"51","author":"Talley N","year":"2002","journal-title":"Gut"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80054-4"}],"container-title":["Archives of Drug Information"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1753-5174.2008.00012.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1753-5174.2008.00012.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:59:35Z","timestamp":1697072375000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1753-5174.2008.00012.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1111\/j.1753-5174.2008.00012.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1753-5174.2008.00012.x","archive":["Portico"],"relation":{},"ISSN":["1753-5174","1753-5174"],"issn-type":[{"value":"1753-5174","type":"print"},{"value":"1753-5174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}